Cost-effectiveness review of inpatient lung cancer care

A cost-effectiveness evaluation of routine inpatient care for lung cancer patients in rural Anhui, China: methods and measures

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN25595562

Enrollment

5000

Registered

2017-06-27

Start date

2017-07-01

Completion date

Unknown

Last updated

2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer Cancer Malignant neoplasm of bronchus and lung

Interventions

The study adopts a retrospective cohort study design and proceeds in 5 steps. Step 1 defines 4 main categories of study variables including clinical procedures, direct cost and effectiveness of the pr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Lung cancer patients diagnosed between 01/07/2014 and 30/06/2015 from rural Anhui 2. Aged 18 or older

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Gains in months of survival per unit cost 2. Gains in months of progression-free survival per unit cost Measured at endpoint of the study, i.e., some 2 to 2.5 years after first diagnosis of lung cancer	—

Secondary

Measure	Time frame
1. Gains in quality of life score per unit cost 2. Gains in Karnofsky Performance status (KPS) per unit cost 3. Per unit cost gains in compiled indices of symptoms (e.g., chronic cough, chest pain, dysphonia, wasting syndrome, fever) 4. Lung functions (e.g., forced vital capacity, forced expiratory volume in one second, TLCO-SB) 5. Imaging findings (e.g., number of nodes identified in the lung, maximum size of the nodes, presence of abnormalities with the mediastinum or hilum, presence of pleura or pericardial effusion) 6. Biological test findings (e.g., value of CEA, CA125, proGRP, SCC, NSE) 7. Complications and comorbidities (e.g., presence of superior vena cava syndrome, superior vena cava syndrome, cerebral thrombosis or cerebral hemorrhage, chronic fibrous pneumonia, pulmonary embolism, cardiac insufficiency, arrhythmi) Measured at each episode of hospitalization, i.e., at 4 to 6 time points after the first diagnosis of lung cancer depending on actual times of hospitalization due to the lung cancer by individual patients	—

Measure

Time frame

1. Gains in quality of life score per unit cost 2. Gains in Karnofsky Performance status (KPS) per unit cost 3. Per unit cost gains in compiled indices of symptoms (e.g., chronic cough, chest pain, dysphonia, wasting syndrome, fever) 4. Lung functions (e.g., forced vital capacity, forced expiratory volume in one second, TLCO-SB) 5. Imaging findings (e.g., number of nodes identified in the lung, maximum size of the nodes, presence of abnormalities with the mediastinum or hilum, presence of pleura or pericardial effusion) 6. Biological test findings (e.g., value of CEA, CA125, proGRP, SCC, NSE) 7. Complications and comorbidities (e.g., presence of superior vena cava syndrome, superior vena cava syndrome, cerebral thrombosis or cerebral hemorrhage, chronic fibrous pneumonia, pulmonary embolism, cardiac insufficiency, arrhythmi) Measured at each episode of hospitalization, i.e., at 4 to 6 time points after the first diagnosis of lung cancer depending on actual times of hospitalization due to the lung cancer by individual patients

—

Countries

China

Contacts

Public ContactXinrong Shen

xinrongshen@sina.com+86 (0)551 5116395

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 24, 2026